Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?

Nature Reviews Cardiology

Volumn 10, Issue 3, 2013, Pages 121-122

  Agrawal, Kush ^a   Bhatt, Deepak L ^b  

^a BOSTON MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CANGRELOR; CLOPIDOGREL; HEPARIN; PLACEBO; PRASUGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTERY CONSTRICTION; CORONARY REPERFUSION; DRUG ABSORPTION; DRUG INHIBITION; DRUG POTENCY; FIRST PASS EFFECT; HEART OUTPUT; HEPARINIZATION; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYMPATHETIC TONE; THROMBOCYTE AGGREGATION INHIBITION; CORONARY ARTERY THROMBOSIS; HEART INFARCTION; NOTE; TREATMENT OUTCOME;

ADENOSINE; CORONARY THROMBOSIS; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RECURRENCE; THIOPHENES; TREATMENT OUTCOME;

EID: 84880179194     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.199     Document Type: Review

References (10)

1. Yousuf, O. & Bhatt, D. L. The evolution of antiplatelet therapy in cardiovascular disease. Nat. Rev. Cardiol. 8, 547-559 (2011).
2. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
3. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
4. Montalescot, G. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373, 723-731 (2009).
5. Steg, P. G. et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122, 2131-2141 (2010).
6. Alexopoulos, D. et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 5, 797-804 (2012).
7. Bhatt, D. L. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N. Engl. J. Med. 357, 2078-2081 (2007). (Pubitemid 350106717)
8. Heestermans, A. A. et al. Impaired bio-availability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb. Res. 122, 776-781 (2008).
9. Bhatt, D. L. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361, 2330-2341 (2009).
10. Leonardi, S. et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am. Heart J. 5, 768-776e2 (2012).